Press releases
You will be able to find all of our recent press releases. You can search by keyword or filter by year/business category to quickly find what you need.
You may also want to view our USA press releases and Asia press releases.
Press releases for our local operating companies can be viewed on our individual country websites.
Filter by
-
New Phase III data shows greater treatment response with GSK’s Benlysta® (belimumab) vs placebo in patients with highly active SLE
BLISS-SC builds on an extensive clinical trial programme for belimumab, which is the largest clin...
Read more -
ViiV Healthcare announces public tender agreement with Botswana Ministry of Health for dolutegravir
Agreement supports the first ‘Treat All’ programme for HIV in sub-Saharan Africa, where 70% of pe...
Read more -
Regulatory update on US filing plans for closed triple combination therapy FF/UMEC/VI in patients with COPD
Acceleration of filing of US New Drug Application now expected by end of 2016
Read more -
Board and Committee changes
Dr Vivienne Cox, CBE, has been appointed to the Board of the Company as a Non-Executive Director ...
Read more -
StrimvelisTM receives European marketing authorisation to treat very rare disease, ADA-SCID
GSK, Fondazione Telethon and Ospedale San Raffaele gain approval to provide life-saving gene ther...
Read more -
GSK, Fondazione Telethon and Ospedale San Raffaele announce publication of pivotal safety and efficacy of gene therapy for children with ADA-SCID
GSK today announced the publication in BLOOD of the long-term safety and efficacy data from an an...
Read more -
Salford Lung Study results show COPD patients treated with Relvar® Ellipta® achieve superior reduction in exacerbations compared with ‘usual care’
Pioneering GSK study provides important new data on the effectiveness of Relvar Ellipta (FF/VI) w...
Read more -
GSK presents new data from Breo® Ellipta® SUMMIT study in patients with COPD at ATS Conference
GSK presents new data at the American Thoracic Society Conference from two pre-specified analyses...
Read more -
GSK presents efficacy data for Anoro® Ellipta® in COPD patients who remained symptomatic on tiotropium
GSK and Innoviva, Inc. announce results from data presented at the American Thoracic Society 2016...
Read more -
GSK’s Bexsero®▼achieves primary and secondary endpoints with reduced 3-dose schedule (2+1) in safety and immunogenicity study in infants and children
GSK today presented new data for its meningococcal group B vaccine, Bexsero®,1 [Meningococcal gr...
Read more -
European agency endorses antiseptic gel, developed through GSK and Save the Children partnership, for newborn umbilical cord infections in developing countries
Major milestone for the GSK and Save the Children partnership and its mission to help save the li...
Read more -
Results announcement for the first quarter 2016
GSK delivers strong Q1 performance with sales of £6.2 billion (+8% CER), core EPS 19.8p (+8% CER)...
Read more -
GSK statement on pneumococcal vaccine pricing
For many years we have been working hard, in partnership with others, to develop vaccines against...
Read more -
ViiV Healthcare extends Medicines Patent Pool licence agreement for dolutegravir to cover all lower middle-income countries
Follows announcement by majority shareholder GSK to expand graduated approach to patents and inte...
Read more -
GSK announces start of a phase II study to evaluate an anti GM-CSF antibody for inflammatory hand osteoarthritis
GSK announces the start of a phase II study to evaluate the efficacy and safety of an investigati...
Read more -
GSK opens new state of the art respiratory manufacturing facility in Ware, UK
GSK today opens a £56 million state of the art manufacturing facility, creating 150 new jobs in t...
Read more -
GSK receives positive CHMP opinion in Europe for Strimvelis™, the first gene therapy to treat very rare disease, ADA-SCID
GSK announces a positive opinion recommending marketing authorisation for Strimvelis to treat pat...
Read more -
GSK expands graduated approach to patents and intellectual property to widen access to medicines in the world’s poorest countries
GSK has a deep commitment to improving healthcare by developing innovative new medicines and wide...
Read more -
GSK receives marketing authorisation for Nucala® (mepolizumab) in Japan
GSK announces that the Japanese Ministry of Health, Labour and Welfare has granted approval for N...
Read more -
Sir Andrew Witty to retire from GSK in March 2017
In the publication of its 2015 Annual Report to shareholders, GSK plc today announced that Sir An...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research
Science can improve health and well-being in so many ways, from the development of everyday convenience healthcare products through to life-saving medicines and vaccines
-
Investors
Information and tools for investors including share and dividend information, share price analysis, latest news and corporate reporting
